The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
== Production == In September 2005, lead singer Corey Taylor announced that Stone Sour would return with a second album. He said that they had written over 30 songs, some during the writing process of Vol. 3: (The Subliminal Verses), the third album by vocalist Taylor and guitarist James Root's other band Slipknot, and that they were working on demoing the tracks before entering the studio. Dave Fortman was originally scheduled to produce the album, but on January 22, 2006, Stone Sour began working on the album with producer Nick Raskulinecz at Dave Grohl's personal studio (Studio 606), in Los Angeles. Time in the studio began with a week of pre-production, during which the guitarist Josh Rand said that Raskulinecz "pushed [the band] to the brink and back" to help fine-tune the songs they had previously written. first album, writing for Come What(ever) May was by all members. Following this, the band set out to record 18 tracks and work began on recording Joel Ekman's drum tracks. However, Ekman was forced to leave the studio after four weeks because of his young son's diagnosis of a brainstem glioma. With the fate of the album in jeopardy, Stone Sour recruited Mayorga, ex-Soulfly, as a session drummer. Mayorga recorded drums for all but two tracks on the album, Godsmack drummer Shannon Larkin performed on the track "30/30-150" and guitarist Root performed drums on the bonus track "The Day I Let Go". In an interview with Revolver during the recording process, the vocalist Taylor talked about the differences between this album and their previous album, Stone Sour.
=== Prohibited content === Facepunch Studios blacklists servers that are malicious, depict sexual violence, or contain content that is not safe for work but not marked as such. In April 2023, following a Twitter poll with close to 50,000 respondents, the company additionally banned the glorification of Nazism, including the display of swastikas and the Nazi salute.
== Clinical significance == Narcolepsy is associated with a marked reduction in the number of orexinergic projection neurons from the lateral hypothalamus and very low orexin peptides in cerebrospinal fluid. This has been identified as the mechanism responsible for narcoleptic symptoms. Evidence suggest that OX1 neurons that synapse onto the dorsal nucleus of the vagus nerve and parts of the brain stem may play a role in the pathophysiology of chronic pain and visceral hypersensitivity in functional gastrointestinal disorders.
==== Railway ==== With the opening of the railway from London to Liverpool, Holyhead lost the London-Dublin mail contract in 1839 to the Port of Liverpool. Only after the completion of the Chester and Holyhead Railway in 1850, and the building of Holyhead railway station, did the Irish Mail return to Holyhead, operated from London Euston by the London and North Western Railway.
=== Academic service === Ben-Tal has served on the editorial boards of scientific journals including eLife, Journal of Biological Chemistry, and BBA Biomembranes. At present he is Senior Editor with Protein Science (since 2021), and Associate Editor with PLoS Computational Biology (since 2013). He has also participated in scientific committees associated with international computational biology conferences, including the Intelligent Systems for Molecular Biology (ISMB) and the European Conference on Computational Biology (ECCB). He is a member of the Edmond J. Safra Center for Bioinformatics at Tel Aviv University, where his laboratory is part of the center's research community.
Sources: en.wikipedia.org
=== January === 1 January – Police Scotland launch a murder investigation following the death of a 38-year-old man who was shot outside an Edinburgh pub shortly before midnight on New Year's Eve. A second man injured during the incident has been taken to hospital. The deceased man is subsequently named as Marc Webley. 3 January – Police say they are "extremely concerned" for the safety of Laura Wilkie, a 43-year-old woman from Ayr, who has been missing since 18 December 2023. 4 January – Owners of American XL bully dogs in England and Wales are warned not to rehome them in Scotland as they become a banned breed under the Dangerous Dogs Act 1991 in England and Wales. Police searching for Laura Wilkie find a body at Rozelle Park in Ayr, close to where she was last seen. 5 January – Fugitive Nicholas Rossi, wanted in the United States on rape charges, is extradited from Scotland. 6 January – A 32-year-old man and 25-year-old woman have been arrested and charged with murder over the death of Marc Webley on New Year's Eve, police have confirmed. 8 January – Scottish Government papers reveal that a fragment of the Stone of Destiny gifted to Alex Salmond in 2008, and thought to be lost, is being held by the Scottish National Party at its headquarters. 9 January – BBC News reports that a ban on American XL bully dogs is likely in Scotland by the end of January.
Colombia is ethnically diverse, its people descending from the original Native inhabitants, Spanish conquistadors, Africans originally brought to the country as slaves, and 20th-century immigrants from Europe and the Middle East, all contributing to a diverse cultural heritage. The demographic distribution reflects a pattern that is influenced by colonial history. Whites live all throughout the country, mainly in urban centers and the burgeoning highland and coastal cities. The populations of the major cities also include mestizos. Mestizo campesinos (people living in rural areas) also live in the Andean highlands where some Spanish conquerors mixed with the women of Amerindian chiefdoms. Mestizos include artisans and small tradesmen that have played a major part in the urban expansion of recent decades. In a study by the American Journal of Physical Anthropology, Colombians have an average ancestry of 47% Amerindian DNA, 42% European DNA, and 11% African DNA. The 2018 census reported that the "non-ethnic population", consisting of whites and mestizos (those of mixed European and Amerindian ancestry), constituted 87.6% of the national population. 6.7% is of African ancestry. Indigenous Amerindians constitute 4.3% of the population. Raizal people constitute 0.06% of the population. Palenquero people constitute 0.02% of the population. 0.01% of the population are Roma.
Yusta, B; Baggio, L.L.; Estall, J.L.; Koehler, J.A.; Holland, D.P.; Li, H; Pipeleers, D; Ling, Z; Drucker, D.J. (2006). "GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress". Cell Metabolism. 4 (5): 391–406. doi:10.1016/j.cmet.2006.10.001. PMID 17084712. Drucker, D. J.; Buse, J. B.; Taylor, K.; Kendall, D. M.; Trautmann, M.; Zhuang, D.; Porter, L. (2008). "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study". The Lancet. 372 (9645): 1240–1250. doi:10.1016/S0140-6736(08)61206-4. PMID 18782641. S2CID 12667840. Kim, M.; Platt, M.; Shibasaki, T.; Quaggin, S.; Backx, P.H.; Seino, S.; Simpson, J.; Drucker, D.J. (2013). "GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure". Nature Medicine. 19 (5): 567–575. doi:10.1038/nm.3128. PMID 23542788. Wong, C.K.; Yusta, B.; Koehler, J.A.; Baggio, L.L.; McLean, B.A.; Matthews, D.; Seeley, R.J.; Drucker, D.J. (2022). "Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation". Cell Metabolism. 34 (10): 1514–1531. doi:10.1016/j.cmet.2022.08.003. PMID 36027914. Wong, C.K.; MacLean, B.A.; Baggio, L.L.; Koehler, J.A.; Hammoud, R.; Rittig, N.; Yabut, J.M.; Seeley, R.J.; Brown, T.K.; Drucker, D.J. (2024). "Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation". Cell Metabolism. 36 (1): 130–143. doi:10.1016/j.cmet.2023.11.009.
Molybdenum(II) chloride MoCl2, which exists as the hexamer Mo6Cl12 and the related dianion [Mo6Cl14]2-. Molybdenum(III) chloride MoCl3, a dark red solid, which converts to the anion trianionic complex [MoCl6]3-. Molybdenum(IV) chloride MoCl4, a black solid, which adopts a polymeric structure. Molybdenum(V) chloride MoCl5 dark green solid, which adopts a dimeric structure. Molybdenum(VI) chloride MoCl6 is a black solid, which is monomeric and slowly decomposes to MoCl5 and Cl2 at room temperature. The accessibility of these oxidation states depends quite strongly on the halide counterion: although molybdenum(VI) fluoride is stable, molybdenum does not form a stable hexachloride, pentabromide, or tetraiodide. Like chromium and some other transition metals, molybdenum forms quadruple bonds, such as in Mo2(CH3COO)4 and [Mo2Cl8]4−. The Lewis acid properties of the butyrate and perfluorobutyrate dimers, Mo2(O2CR)4 and Rh2(O2CR) 4, have been reported. The oxidation state 0 and lower are possible with carbon monoxide as ligand, such as in molybdenum hexacarbonyl, Mo(CO)6.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.